Camurus AB (publ) (CAMX.ST)
SEK 568.0
(1.07%)
SEK 568.0
(1.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.71 Billion SEK | 79.52% |
| 2022 | 956.34 Million SEK | 59.24% |
| 2021 | 600.57 Million SEK | 78.74% |
| 2020 | 335.99 Million SEK | 218.16% |
| 2019 | 105.6 Million SEK | 114.12% |
| 2018 | 49.32 Million SEK | -9.18% |
| 2017 | 54.3 Million SEK | -52.25% |
| 2016 | 113.73 Million SEK | -26.53% |
| 2015 | 154.79 Million SEK | -25.65% |
| 2014 | 208.2 Million SEK | 5.31% |
| 2013 | 197.71 Million SEK | 107.68% |
| 2012 | 95.2 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 390 Million SEK | 4.12% |
| 2024 Q2 | 444.86 Million SEK | 14.07% |
| 2023 Q3 | 383.98 Million SEK | -43.05% |
| 2023 Q1 | 284.03 Million SEK | 5.98% |
| 2023 FY | 1.71 Billion SEK | 79.52% |
| 2023 Q4 | 374.56 Million SEK | -2.45% |
| 2023 Q2 | 674.26 Million SEK | 137.39% |
| 2022 Q4 | 268.01 Million SEK | 11.04% |
| 2022 Q1 | 220.28 Million SEK | 20.51% |
| 2022 Q2 | 226.68 Million SEK | 2.91% |
| 2022 Q3 | 241.36 Million SEK | 6.48% |
| 2022 FY | 956.34 Million SEK | 59.24% |
| 2021 Q4 | 182.79 Million SEK | 18.71% |
| 2021 Q2 | 137.89 Million SEK | 9.53% |
| 2021 Q1 | 125.89 Million SEK | 19.26% |
| 2021 FY | 600.57 Million SEK | 78.74% |
| 2021 Q3 | 153.98 Million SEK | 11.67% |
| 2020 Q3 | 100.26 Million SEK | 23.97% |
| 2020 Q4 | 105.56 Million SEK | 5.3% |
| 2020 FY | 335.99 Million SEK | 218.16% |
| 2020 Q1 | 49.29 Million SEK | 40.75% |
| 2020 Q2 | 80.87 Million SEK | 64.05% |
| 2019 Q1 | 18.49 Million SEK | 136.95% |
| 2019 Q3 | 40.17 Million SEK | 237.24% |
| 2019 FY | 105.6 Million SEK | 114.12% |
| 2019 Q2 | 11.91 Million SEK | -35.58% |
| 2019 Q4 | 35.02 Million SEK | -12.82% |
| 2018 Q4 | 7.8 Million SEK | -60.1% |
| 2018 FY | 49.32 Million SEK | -9.18% |
| 2018 Q3 | 19.56 Million SEK | 167.42% |
| 2018 Q2 | 7.31 Million SEK | -50.03% |
| 2018 Q1 | 14.63 Million SEK | 168.21% |
| 2017 FY | 54.3 Million SEK | -52.25% |
| 2017 Q4 | 5.45 Million SEK | -56.41% |
| 2017 Q3 | 12.52 Million SEK | -34.58% |
| 2017 Q2 | 19.13 Million SEK | 11.32% |
| 2017 Q1 | 17.19 Million SEK | -53.69% |
| 2016 Q2 | 25.83 Million SEK | 27.6% |
| 2016 Q3 | 30.53 Million SEK | 18.18% |
| 2016 Q4 | 37.12 Million SEK | 21.6% |
| 2016 FY | 113.73 Million SEK | -26.53% |
| 2016 Q1 | 20.24 Million SEK | -44.29% |
| 2015 Q1 | 58.56 Million SEK | -59.57% |
| 2015 Q2 | 22.65 Million SEK | -61.31% |
| 2015 Q3 | 37.23 Million SEK | 64.31% |
| 2015 Q4 | 36.34 Million SEK | -2.4% |
| 2015 FY | 154.79 Million SEK | -25.65% |
| 2014 FY | 208.2 Million SEK | 5.31% |
| 2014 Q4 | 144.87 Million SEK | 326.21% |
| 2014 Q3 | 33.99 Million SEK | 0.0% |
| 2013 FY | 197.71 Million SEK | 107.68% |
| 2012 FY | 95.2 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alzinova AB (publ) | 270 Thousand SEK | -635770.37% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | -178.712% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | -42.254% |
| Saniona AB (publ) | 16.84 Million SEK | -10095.071% |
| Simris Alg AB (publ) | 4.35 Million SEK | -39331.557% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -60738.058% |
| NextCell Pharma AB | 10.66 Million SEK | -15998.435% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -15187.982% |
| AcouSort AB (publ) | 10.55 Million SEK | -16171.917% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -2854.635% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 158.23 Million SEK | -985.021% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 28.48 Million SEK | -5926.784% |
| Kancera AB (publ) | 1.03 Million SEK | -165779.227% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -85145.78% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -3239239.623% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -10364.131% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | -907.305% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | 3000.00 SEK | -57228233.333% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | -619.163% |
| Xintela AB (publ) | 78 Thousand SEK | -2200989.744% |
| Ziccum AB (publ) | 3.74 Million SEK | -45719.322% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -238020.666% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | 5.54 Million SEK | -30867.059% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -1320553.846% |
| Intervacc AB (publ) | 8.01 Million SEK | -21320.462% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -3300.713% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -39151.257% |
| Corline Biomedical AB | 25.03 Million SEK | -6759.169% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -30136.879% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -3811.176% |
| Aptahem AB (publ) | 2.63 Million SEK | -65163.388% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -2229575.325% |
| Fluicell AB (publ) | 3.33 Million SEK | -51333.493% |
| Biovica International AB (publ) | 7.29 Million SEK | -23450.754% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -142614.048% |
| Abliva AB (publ) | 137 Thousand SEK | -1253075.182% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -2880.642% |
| 2cureX AB (publ) | 155 Thousand SEK | -1107545.161% |
| I-Tech AB | 120.86 Million SEK | -1320.516% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | -1180.333% |
| Cyxone AB (publ) | 5.14 Million SEK | -33249.845% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -24252.482% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 1.44 Million SEK | -118877.824% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 71.46 Million SEK | -2302.499% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -4774.645% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -117249.729% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -7464465.217% |